For Pharmacology: A Patient- Centered Nursing Process Approach, 9th Edition
By Mccuistion Questions And Answers Graded A+
PRINTEND PDF|ORIGINAL DIRECT FROM PUBLISHER|100%
VERIFIED ANSWERS|DOWLOAD IMMEDIATELY AFTER THE ORDER
9TH EDITION
Complete Test Bank, All Chapter Are Included
For More Documents Search (Testbankproferssor.Stuvia)
,table of contents
chapter 01: drug development and ethical considerations .............................................................. 4
chapter 02: pharmacokinetics, pharmacodynamics, andpharmacogenetics ................................. 11
chapter 03: cultural considerations .............................................................................................. 18
chapter 04: complementary and alternative therapies .................................................................. 21
chapter 05: pediatric considerations............................................................................................. 26
chapter 06: geriatric considerations ............................................................................................. 31
chapter 07: drugs in substance use disorder................................................................................ 36
chapter 08: the nursing process and patient-centered care .......................................................... 45
chapter 09: safety and quality ...................................................................................................... 49
chapter 10: drug administration.................................................................................................... 54
chapter 11: drug calculations ....................................................................................................... 58
chapter 12: fluid volume and electrolytes ..................................................................................... 63
chapter 13: vitamin and mineral replacement ............................................................................... 70
chapter 14: nutritional support ..................................................................................................... 76
chapter 15: adrenergic agonists and antagonists ......................................................................... 83
chapter 16: cholinergic agonists and antagonists ......................................................................... 89
chapter 17: stimulants.................................................................................................................. 94
chapter 18: depressants .............................................................................................................. 98
chapter 19: antiseizure drugs ..................................................................................................... 103
chapter 20: drugs for parkinsonism and alzheimer's disease ..................................................... 109
chapter 21: drugs for neuromuscular disorders and musclespasms........................................... 114
chapter 22: antipsychotics and anxiolytics ................................................................................. 120
chapter 23: antidepressants and mood stabilizers ..................................................................... 126
chapter 24: antiinflammatories ................................................................................................... 132
chapter 25: analgesics ............................................................................................................... 144
chapter 26: antibacterials ........................................................................................................... 150
chapter 27: antituberculars, antifungals, and antivirals ............................................................... 159
chapter 28: peptides, antimalarials, and anthelmintics ............................................................... 165
chapter 29: hiv- and aids-related drugs ...................................................................................... 175
chapter 30: transplant drugs ...................................................................................................... 179
chapter 31: vaccines .................................................................................................................. 182
chapter 32: anticancer drugs ..................................................................................................... 186
chapter 33: targeted therapies to treat cancer ............................................................................ 190
chapter 34: biologic response modifiers ..................................................................................... 192
,chapter 35: upper respiratory disorders ..................................................................................... 196
chapter 36: lower respiratory disorders ...................................................................................... 200
chapter 37: cardiac glycosides, antianginals, andantidysrhythmics ............................................ 204
chapter 38: diuretics .................................................................................................................. 211
chapter 39: antihypertensives .................................................................................................... 214
chapter 40: anticoagulants, antiplatelets, and thrombolytics....................................................... 220
chapter 41: antihyperlipidemics and peripheral vasodilators ...................................................... 225
chapter 42: gastrointestinal tract disorders ................................................................................ 229
chapter 43: antiulcer drugs ........................................................................................................ 240
chapter 44: eye and ear disorders.............................................................................................. 245
chapter 45: dermatologic disorders ............................................................................................ 248
chapter 46: pituitary, thyroid, parathyroid, and adrenaldisorders ................................................ 252
chapter 47: antidiabetics ............................................................................................................ 258
chapter 48: urinary disorders ..................................................................................................... 264
chapter 49: pregnancy and preterm labor .................................................................................. 268
chapter 50: labor, delivery, and postpartum ............................................................................... 273
chapter 51: neonatal and newborn ............................................................................................. 276
chapter 52: women's reproductive health ................................................................................... 280
chapter 53: men's reproductive health ....................................................................................... 283
chapter 54: sexually transmitted infections ................................................................................ 286
chapter 55: adult and pediatric emergency drugs....................................................................... 290
, chapter 01: drug development and ethical considerations
multiple choice
1. the nurse is preparing to administer a schedule ii injectable drug and is drawing up half of
the contents of a single-use vial. which nursing action is correct?
a. ask another nurse to observe and cosign wasting the remaining drug from the vial.
b. keep the remaining amount in the patient’s drawer to give at the next dose.
c. record the amount unused in the patient’s medication record.
d. dispose of the vial with the remaining drug into a locked collection box.
ans: a
schedule ii drugs are controlled substances, and all must be accounted for. when wasting a
portion of a drug, another nurse should observe and cosign that a drug was wasted.
dif: cognitive level: applying (application) top:
nursing process: nursing intervention
msc: nclex: physiological integrity: pharmacological and parenteral therapies
2. a patient is prescribed a medication and asks the nurse if the drug is available in a generic
form. the nurse understands that a generic medication will have a name that
a. is a registered trademark.
b. is always capitalized.
c. describes the drugs chemical structure.
d. is non-proprietary.
ans: d
the generic name is the official, non-proprietary name for a drug. the brand name is the
trademark name and is always capitalized. the chemical name describes the chemical structureof
the drug.
dif: cognitive level: understanding (comprehension)top:
nursing process: n/a
msc: nclex: physiological integrity: pharmacological and parenteral therapies
3. a patient receives a prescription on which the provider has noted that a generic
medication may be given.the patient asks the nurse what this means. what will the nurse tell
the patientabout generic drugs?
a. they contain the same inert ingredients as brand-name drugs.
b. they have chemical structures that are identical to proprietary drugs.
c. they tend to be less expensive than brand-name drugs.
d. they undergo extensive testing before they are marketed.
ans: c
generic drugs are approved by the fda if they are proved to be bioequivalent to the brand-
name drug. they tend to be less expensive because manufacturers of these drugs do not have
to do the extensive testing required of brand-name drugs before marketing. they are not
identical to brand-name drugs and often have different inert ingredients.
dif: cognitive level: applying (application)
top: nursing process: nursing intervention: patient teachingmsc:
nclex: management of client care
4. the nurse reviews information about a drug and notes the initials usp after the drugs official
name. the nurse understands that this designation indicates the drug
By Mccuistion Questions And Answers Graded A+
PRINTEND PDF|ORIGINAL DIRECT FROM PUBLISHER|100%
VERIFIED ANSWERS|DOWLOAD IMMEDIATELY AFTER THE ORDER
9TH EDITION
Complete Test Bank, All Chapter Are Included
For More Documents Search (Testbankproferssor.Stuvia)
,table of contents
chapter 01: drug development and ethical considerations .............................................................. 4
chapter 02: pharmacokinetics, pharmacodynamics, andpharmacogenetics ................................. 11
chapter 03: cultural considerations .............................................................................................. 18
chapter 04: complementary and alternative therapies .................................................................. 21
chapter 05: pediatric considerations............................................................................................. 26
chapter 06: geriatric considerations ............................................................................................. 31
chapter 07: drugs in substance use disorder................................................................................ 36
chapter 08: the nursing process and patient-centered care .......................................................... 45
chapter 09: safety and quality ...................................................................................................... 49
chapter 10: drug administration.................................................................................................... 54
chapter 11: drug calculations ....................................................................................................... 58
chapter 12: fluid volume and electrolytes ..................................................................................... 63
chapter 13: vitamin and mineral replacement ............................................................................... 70
chapter 14: nutritional support ..................................................................................................... 76
chapter 15: adrenergic agonists and antagonists ......................................................................... 83
chapter 16: cholinergic agonists and antagonists ......................................................................... 89
chapter 17: stimulants.................................................................................................................. 94
chapter 18: depressants .............................................................................................................. 98
chapter 19: antiseizure drugs ..................................................................................................... 103
chapter 20: drugs for parkinsonism and alzheimer's disease ..................................................... 109
chapter 21: drugs for neuromuscular disorders and musclespasms........................................... 114
chapter 22: antipsychotics and anxiolytics ................................................................................. 120
chapter 23: antidepressants and mood stabilizers ..................................................................... 126
chapter 24: antiinflammatories ................................................................................................... 132
chapter 25: analgesics ............................................................................................................... 144
chapter 26: antibacterials ........................................................................................................... 150
chapter 27: antituberculars, antifungals, and antivirals ............................................................... 159
chapter 28: peptides, antimalarials, and anthelmintics ............................................................... 165
chapter 29: hiv- and aids-related drugs ...................................................................................... 175
chapter 30: transplant drugs ...................................................................................................... 179
chapter 31: vaccines .................................................................................................................. 182
chapter 32: anticancer drugs ..................................................................................................... 186
chapter 33: targeted therapies to treat cancer ............................................................................ 190
chapter 34: biologic response modifiers ..................................................................................... 192
,chapter 35: upper respiratory disorders ..................................................................................... 196
chapter 36: lower respiratory disorders ...................................................................................... 200
chapter 37: cardiac glycosides, antianginals, andantidysrhythmics ............................................ 204
chapter 38: diuretics .................................................................................................................. 211
chapter 39: antihypertensives .................................................................................................... 214
chapter 40: anticoagulants, antiplatelets, and thrombolytics....................................................... 220
chapter 41: antihyperlipidemics and peripheral vasodilators ...................................................... 225
chapter 42: gastrointestinal tract disorders ................................................................................ 229
chapter 43: antiulcer drugs ........................................................................................................ 240
chapter 44: eye and ear disorders.............................................................................................. 245
chapter 45: dermatologic disorders ............................................................................................ 248
chapter 46: pituitary, thyroid, parathyroid, and adrenaldisorders ................................................ 252
chapter 47: antidiabetics ............................................................................................................ 258
chapter 48: urinary disorders ..................................................................................................... 264
chapter 49: pregnancy and preterm labor .................................................................................. 268
chapter 50: labor, delivery, and postpartum ............................................................................... 273
chapter 51: neonatal and newborn ............................................................................................. 276
chapter 52: women's reproductive health ................................................................................... 280
chapter 53: men's reproductive health ....................................................................................... 283
chapter 54: sexually transmitted infections ................................................................................ 286
chapter 55: adult and pediatric emergency drugs....................................................................... 290
, chapter 01: drug development and ethical considerations
multiple choice
1. the nurse is preparing to administer a schedule ii injectable drug and is drawing up half of
the contents of a single-use vial. which nursing action is correct?
a. ask another nurse to observe and cosign wasting the remaining drug from the vial.
b. keep the remaining amount in the patient’s drawer to give at the next dose.
c. record the amount unused in the patient’s medication record.
d. dispose of the vial with the remaining drug into a locked collection box.
ans: a
schedule ii drugs are controlled substances, and all must be accounted for. when wasting a
portion of a drug, another nurse should observe and cosign that a drug was wasted.
dif: cognitive level: applying (application) top:
nursing process: nursing intervention
msc: nclex: physiological integrity: pharmacological and parenteral therapies
2. a patient is prescribed a medication and asks the nurse if the drug is available in a generic
form. the nurse understands that a generic medication will have a name that
a. is a registered trademark.
b. is always capitalized.
c. describes the drugs chemical structure.
d. is non-proprietary.
ans: d
the generic name is the official, non-proprietary name for a drug. the brand name is the
trademark name and is always capitalized. the chemical name describes the chemical structureof
the drug.
dif: cognitive level: understanding (comprehension)top:
nursing process: n/a
msc: nclex: physiological integrity: pharmacological and parenteral therapies
3. a patient receives a prescription on which the provider has noted that a generic
medication may be given.the patient asks the nurse what this means. what will the nurse tell
the patientabout generic drugs?
a. they contain the same inert ingredients as brand-name drugs.
b. they have chemical structures that are identical to proprietary drugs.
c. they tend to be less expensive than brand-name drugs.
d. they undergo extensive testing before they are marketed.
ans: c
generic drugs are approved by the fda if they are proved to be bioequivalent to the brand-
name drug. they tend to be less expensive because manufacturers of these drugs do not have
to do the extensive testing required of brand-name drugs before marketing. they are not
identical to brand-name drugs and often have different inert ingredients.
dif: cognitive level: applying (application)
top: nursing process: nursing intervention: patient teachingmsc:
nclex: management of client care
4. the nurse reviews information about a drug and notes the initials usp after the drugs official
name. the nurse understands that this designation indicates the drug
